インシリコ創薬の世界市場：市場規模・シェア分析 - 動向、促進要因、競合情勢、将来予測 (2024年～2030年)

市場概要

世界のインシリコ創薬市場は、2023年に28億2,970万米ドルの収益を上げ、2030年には56億9,140万米ドルに達すると予測され、予測期間のCAGRは10.6%で成長します。同産業の発展は、投薬ミスを減らすことが重視されるようになったこと、計算生物学の技術的向上、創薬におけるクラウドベースの用途が拡大していることなどが背景にあります。

さらに、計算生物学の進歩は、シーケンシングの解析段階とともにデータ処理の簡素化を促進し、より短い納期と正確な結果を生み出しています。これらすべての機能強化が、柔軟なノードの最適化とストレージの統合という新たな動向を引き起こし、主要な業界リーダーがこれに注目しています。

クラウド制御ソフトウェアの普及拡大は、インシリコ創薬市場の成長を促す主な要因の一つです。クラウドコンピューティングは、ほぼ無制限の計算資源を得る機会を提供するため、医薬品を研究する研究者は、ニーズに合った量の計算能力を確保することができます。

主な洞察

2023年には、人工知能 (AI) カテゴリーが65%以上のシェアで市場をリードしました。医療におけるデータデジタル化の増大がそれを後押ししました。

SaaSカテゴリーは、約10.8%のCAGRで成長すると推定されています。

CRO (医薬品開発業務受託機関) は、予測期間中に11.0%以上のCAGRで進歩すると予測され、医薬品開発における企業のコストを減少させます。

地域別では、2023年には北米地域が世界のインシリコ創薬産業シェアの50%を占めています。これは、希少疾患の治療に対するニーズとバイオ医薬品企業による研究開発投資の増大が後押ししています。

米国では、医療投資と研究開発投資が大幅に拡大して、2020年には約2,500億米ドルに達しており、それが業界の成長に寄与しています。

アジア太平洋のインシリコ創薬産業は、患者の健康増進を目指した取り組みにより、主にソフトウェアベースの技術で顕著な発展を遂げています。

当レポートでは、世界のインシリコ創薬の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、製品別・ワークフロー別・用途別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：ワークフロー別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：ワークフロー別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：ワークフロー別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• chrodinger Inc.
• Dassault Systemes
• OpenEye Scientific Software
• Chemical Computing Group
• Cresset Biomolecular Discovery Limited
• Insilico Medicine
• Atomwise Inc.
• Evotec
• Charles River Laboratories
• Ligand Pharmaceuticals Incorporated
• Simulation Plus

第31章 付録

Market Overview

The worldwide in-silico drug discovery produced a revenue of USD 2,829.7 million in 2023 and is projected to touch USD 5,691.4 million by 2030, growing at a CAGR of 10.6% over the projection period. The development of the industry can be credited to the growing emphasis on decreasing medication mistakes, technical improvements in computational biology, and the rising use of cloud-based applications in drug discovery.

The worldwide in-silico drug discovery market is also propelled by the fast technical advances in the field of computational biology. Computational methods have been effective in the growth of new medicinal molecules.

In addition, advances in computational biology facilitate the simplification of data processing along with analysis phases of sequencing producing shorter turnaround times and accurate results. All the enhancements have triggered a new trend of flexible node optimization and storage integration that major industry leaders are looking into.

Such integration is expected to decrease the amount of transfer data and to solve the queues in data processing, which in principle will eliminate the downlink from the computational analytical community to the ground.

The growing prevalence of cloud control software is one of the main forces driving the in-silico drug discovery market growth. Researchers who study pharmaceuticals can secure access to the amount of computational power that meets their needs because cloud computing provides the opportunity to get almost unlimited computational resources.

Key Insights

In 2023, the AI category led the market with more than 65% share, propelled by augmented data digitization in health care.

Artificial intelligence confronts issues like analyzing multifaceted clinical difficulties and quickening therapeutic target validation in medication discovery.

It helps in the designing of drugs, chemical synthesis, monitoring, polypharmacology, and repurposing, making it essential to numerous stages of drug advancement.

The SaaS category is estimated to advance at a CAGR of around 10.8% in the in-silico drug discovery industry.

Acceptance of SaaS aids in reducing prices and time taken in drug discovery procedures.

SaaS channels are extensively utilized for virtual screening and aim fishing in drug discovery.

Contract Research Organizations are projected to advance at a CAGR of more than 11.0% during the projection period, decreasing costs for businesses in drug development.

Working with a contract research organization provides sponsors not only with an advantage over the traditional clinical studies but also with a quick opportunity to obtain an entire package of trial solutions for the studies to be successful.

The computer application with the largest market resource was introduced in 2021, commonly used for new drug medication designing and in ADME-tox modeling and off-target prediction.

Pharmacophore systematics is usually used concurrently with molecular docking simulations in order to improve the efficiency of virtual screening assays.

In 2023, the North American region help 50% of the worldwide in-silico drug discovery industry share, boosted by the need for treatments for rare illnesses and augmented research and development investments by biopharmaceutical businesses.

The U.S. experienced substantial development in medical and research and development investments, attaining around USD 250 billion in 2020, contributing to industry growth.

The APAC in-silico drug discovery industry has witnessed prominent development, mainly in software-based techs, reinforced by initiatives aimed at advancing patient health.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by workflow
  • 1.4.3. Market size breakdown, by technology
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Workflow (2017-2030)
• 6.4. Market Revenue, by Technology (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Workflow (2017-2030)
• 7.4. Market Revenue, by Technology (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Workflow (2017-2030)
• 8.4. Market Revenue, by Technology (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Workflow (2017-2030)
• 9.4. Market Revenue, by Technology (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Workflow (2017-2030)
• 10.4. Market Revenue, by Technology (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Workflow (2017-2030)
• 11.4. Market Revenue, by Technology (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Workflow (2017-2030)
• 12.4. Market Revenue, by Technology (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Workflow (2017-2030)
• 13.4. Market Revenue, by Technology (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Workflow (2017-2030)
• 14.4. Market Revenue, by Technology (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Workflow (2017-2030)
• 15.4. Market Revenue, by Technology (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Workflow (2017-2030)
• 16.4. Market Revenue, by Technology (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Workflow (2017-2030)
• 17.4. Market Revenue, by Technology (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Workflow (2017-2030)
• 18.4. Market Revenue, by Technology (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Workflow (2017-2030)
• 19.4. Market Revenue, by Technology (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Workflow (2017-2030)
• 20.4. Market Revenue, by Technology (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Workflow (2017-2030)
• 21.4. Market Revenue, by Technology (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Workflow (2017-2030)
• 22.4. Market Revenue, by Technology (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Workflow (2017-2030)
• 23.4. Market Revenue, by Technology (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Workflow (2017-2030)
• 24.4. Market Revenue, by Technology (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Workflow (2017-2030)
• 25.4. Market Revenue, by Technology (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Workflow (2017-2030)
• 26.4. Market Revenue, by Technology (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Workflow (2017-2030)
• 27.4. Market Revenue, by Technology (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Workflow (2017-2030)
• 28.4. Market Revenue, by Technology (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. chrodinger Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Dassault Systemes
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. OpenEye Scientific Software
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Chemical Computing Group
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Cresset Biomolecular Discovery Limited
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Insilico Medicine
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Atomwise Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Evotec
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Charles River Laboratories
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Ligand Pharmaceuticals Incorporated
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Simulation Plus
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports